← Back to Search

Brachytherapy

Focal Brachytherapy for Prostate Cancer

Q: How many participants are necessary for the successful completion of this research endeavor?

This clinical trial is presently not open for recruitment. It was originally posted on December 1st, 2022 and its last edit occured at the end of November in the same year. However, 1321 trials are actively accepting patients with <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a> while 18 studies require Focal brachytherapy alongside PSMA PET imaging participation.

Q: To what medical conditions has the combination of Focal brachytherapy with PSMA PET imaging been applied?

Focal brachytherapy with PSMA PET imaging, a commonly accepted intervention for elevated prostate specific antigen (PSA), can also be employed to treat other conditions such as suspected metastases, positron emission tomography, and <a href="https://www.withpower.com/clinical-trials/recurrent-prostate-cancer">recurrent prostate cancer</a>.

Q: Is the cutoff age for this trial less than thirty-five years old?

This trial is only open to applicants aged 18-100 years. There are a total of 76 trials available for minors and 1333 clinical studies available for seniors.

Q: Could you inform me of other investigations that have employed Focal brachytherapy with PSMA PET imaging?

Presently, 18 distinct clinical trials are exploring Focal brachytherapy with PSMA PET imaging. None of the ongoing studies have reached Phase 3 yet. While most of these investigations are located in Baltimore, <a href="https://www.withpower.com/clinical-trials/maryland">Maryland</a>, there is a total of 27 research sites engaging in this project.

Q: Are there any available slots left for this research project?

According to information present on clinicaltrials.gov, this medical study is not currently enrolling patients. Initially posted on December 1st 2022, with its last update occurring November 29th 2022, the trial has since closed; however, there are 1339 other trials actively recruiting right now.

Q: Are there any criteria individuals must meet to qualify for enrollment in this trial?

This medical trial is seeking 20 individuals with <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a> between the ages of 18 and 100. To qualify, patients must have a Performance Status of less than 2, Prostate volume under 60 cc (<a href="https://www.withpower.com/clinical-trials/mri">MRI</a> values take precedence over TRUS in case of conflicting results), Adenocarcinoma classification for their type of prostate cancer, Clinical stages T1c -T2a, Nx or N0, Mx or M0 Gleason 6-7 Cancer as well as an International Prostate Symptom Score below 20. Additionally, they will need to agree to undergo DCF-Pyl PSMA PET imaging prior to commencement and

Phase < 1

Recruiting

Led By Daniel Song, MD

Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adenocarcinoma of the prostate

Clinical stages (not radiographic stage) T1c - T2a, Nx or N0, Mx or M0

Timeline

Screening 3 weeks

Treatment Varies

Follow Up post-implant day 30

Awards & highlights

Study Summary

This trial will help the PI learn if 18F-DCFPyl PSMA can help identify clinically significant tumors in patients who will undergo brachytherapy, as well as areas which are uninvolved or contain only clinically insignificant disease.

Who is the study for?

Men with prostate cancer can join this trial if they have a specific type of tumor (adenocarcinoma), are in fairly good health, and their cancer hasn't spread far. Their prostate must be below a certain size, and they need to be able to handle a special PET scan. They can't participate if they've had pelvic radiation before or other major illnesses that could affect the treatment.Check my eligibility

What is being tested?

The study is testing focal brachytherapy guided by an advanced imaging technique using PSMA PET scans. The goal is to target only significant tumors while reducing damage to healthy areas, potentially lowering side effects.See study design

What are the potential side effects?

While not explicitly listed, potential side effects may include discomfort from the procedure, urinary issues due to inflammation or damage near the treated area, and typical risks associated with undergoing PET scans.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with prostate adenocarcinoma.

Select...

My breast cancer is in an early stage and may not have spread to lymph nodes or other parts.

Select...

My prostate cancer has a Gleason score of 6 to 7.

Select...

I can do most of my daily activities without help.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ post-implant day 30

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~post-implant day 30

This trial's timeline: 3 weeks for screening, Varies for treatment, and post-implant day 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percent tumor coverage

Trial Design

1Treatment groups

Experimental Treatment

Group I: Focal brachytherapyExperimental Treatment2 Interventions

Drug: 18F-DCFPyl Other names: PET, PSMA Procedure: Focal brachytherapy with PSMA PET imaging Other names: Radiotherapy, Radiation, Prostate seed implant, Focal therapy

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor

558 Previous Clinical Trials

32,900 Total Patients Enrolled

56 Trials studying Prostate Cancer

3,328 Patients Enrolled for Prostate Cancer

National Institutes of Health (NIH)NIH

2,700 Previous Clinical Trials

7,506,856 Total Patients Enrolled

28 Trials studying Prostate Cancer

6,937 Patients Enrolled for Prostate Cancer

National Cancer Institute (NCI)NIH

13,664 Previous Clinical Trials

40,925,986 Total Patients Enrolled

560 Trials studying Prostate Cancer

507,075 Patients Enrolled for Prostate Cancer

Media Library

Focal Brachytherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT03861676 — Phase < 1

Prostate Cancer Research Study Groups: Focal brachytherapy

Prostate Cancer Clinical Trial 2023: Focal Brachytherapy Highlights & Side Effects. Trial Name: NCT03861676 — Phase < 1

Focal Brachytherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03861676 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are necessary for the successful completion of this research endeavor?

"This clinical trial is presently not open for recruitment. It was originally posted on December 1st, 2022 and its last edit occured at the end of November in the same year. However, 1321 trials are actively accepting patients with prostate cancer while 18 studies require Focal brachytherapy alongside PSMA PET imaging participation."

Answered by AI

To what medical conditions has the combination of Focal brachytherapy with PSMA PET imaging been applied?

"Focal brachytherapy with PSMA PET imaging, a commonly accepted intervention for elevated prostate specific antigen (PSA), can also be employed to treat other conditions such as suspected metastases, positron emission tomography, and recurrent prostate cancer."

Answered by AI

Is the cutoff age for this trial less than thirty-five years old?

"This trial is only open to applicants aged 18-100 years. There are a total of 76 trials available for minors and 1333 clinical studies available for seniors."

Answered by AI

Could you inform me of other investigations that have employed Focal brachytherapy with PSMA PET imaging?

"Presently, 18 distinct clinical trials are exploring Focal brachytherapy with PSMA PET imaging. None of the ongoing studies have reached Phase 3 yet. While most of these investigations are located in Baltimore, Maryland, there is a total of 27 research sites engaging in this project."

Answered by AI

Are there any available slots left for this research project?

"According to information present on clinicaltrials.gov, this medical study is not currently enrolling patients. Initially posted on December 1st 2022, with its last update occurring November 29th 2022, the trial has since closed; however, there are 1339 other trials actively recruiting right now."

Answered by AI

Are there any criteria individuals must meet to qualify for enrollment in this trial?

"This medical trial is seeking 20 individuals with prostate cancer between the ages of 18 and 100. To qualify, patients must have a Performance Status of less than 2, Prostate volume under 60 cc (MRI values take precedence over TRUS in case of conflicting results), Adenocarcinoma classification for their type of prostate cancer, Clinical stages T1c -T2a, Nx or N0, Mx or M0 Gleason 6-7 Cancer as well as an International Prostate Symptom Score below 20. Additionally, they will need to agree to undergo DCF-Pyl PSMA PET imaging prior to commencement and"

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

2023. "Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03861676.

All > Prostate Cancer Baltimore